Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Gastrointestinal 2Breast 2Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 11Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10cabozantinib 8Ipilimumab 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3fludarabine 2entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × budigalimab × Endocrine × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡